ImmunoGen, Inc. Announces Conference Call to Discuss its Third Quarter Fiscal Year 2016 Financial Results
April 11 2016 - 11:30AM
Business Wire
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that
develops novel anticancer therapeutics using its antibody-drug
conjugate (ADC) technology, today announced that the Company will
host a conference call at 8:00 a.m. ET on Friday, April 29, 2016,
to discuss ImmunoGen's financial results for the three-month period
ended March 31, 2016. Management also will provide an update on
mirvetuximab soravtansine and other ImmunoGen product programs.
To access the live call by phone, dial 913-312-0936; the
conference ID is 7099318. The call also may be accessed through the
Investors section of the Company's website, www.immunogen.com.
Following the live webcast, a replay of the call will be available
at the same location through May 13, 2016.
About ImmunoGen, Inc.
ImmunoGen is a clinical-stage biotechnology company that
develops targeted anticancer therapeutics using its proprietary ADC
technology. The Company’s lead product candidate, mirvetuximab
soravtansine, is in Phase 2 testing for the treatment of folate
receptor α-positive ovarian cancer. ImmunoGen’s ADC technology is
used in Roche’s marketed product, Kadcyla®, and in programs in
development by partners Amgen, Bayer, Biotest, CytomX, Lilly,
Novartis, Sanofi and Takeda. More information about the Company can
be found at www.immunogen.com.
Kadcyla® is a registered trademark of Genentech, a member
of the Roche Group.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160411005945/en/
For Investors & Media:ImmunoGen, Inc.Carol Hausner,
781-895-0600info@immunogen.com
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Apr 2023 to Apr 2024